Webinar

Making repurposing programs viable in indications where traditional models stall: lessons from the ReMEdi study in ME/CFS

May 20, 2026
·
11:00 AM ET / 4:00 PM BST
·
1 Hour

Repurposing-target indications usually have populations the traditional site-based model isn't built to reach, endpoints that lack objective measurement, and a commercial profile that won't carry a standard site footprint. Promising assets stall on the study side, not the science. The Phase 2 ReMEdi RCT, sponsored by Tiefenbacher Group, ran a different operational model in ME/CFS: fully decentralized recruitment, remote endpoint capture, and integrated wearable data. This panel discussion covers what the operating model required, what worked, and what was harder than expected.

In this panel, Meri Beckwith, Co-CEO of Lindus, Dr. Simon Bock, Clinical and Market Access, Portfolio & Innovation Manager at Tiefenbacher Group and Dr. Beata Godlewska, Principal Investigator for the ReMEdi trial, sit down to discuss how modern trial design is expanding what's feasible. Drawing on their experience running the ReMEdi study in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), they'll discuss how innovative trial design strategies enabled them to capture regulatory-grade data in a population historically excluded from research, how digital endpoints and wearables are providing more granular, remote, and patient-centric data, and how these methodological choices help sponsors work through the operational hurdles that commonly cause programs to stall. 

The conversation will also cover the regulatory challenges and economic considerations that shape drug repurposing strategies, including how feasibility and commercial attractiveness factor into development decisions. 

‍

What you'll learn

  • Why the traditional CRO operating model doesn't fit most repurposing programs in underserved indications
  • What an alternative operating model needs to keep a repurposing program viable on its commercial profile
  • How regulatory-grade data integrity is maintained in a decentralized, digital-first study, with ReMEdi-specific benchmarks shared where available

‍

Register here

Meet the panel

Meri Beckwith
Co-CEO
Lindus
Moderator
Meri is a former life sciences and healthtech venture capital investor, with an MSc in Biology from the University of Oxford. Serving on the boards of health and biotech companies, he saw CROs repeatedly fail to deliver clinical trials on time and on budget. After participating in a COVID-19 vaccine trial, he saw how fragmented integrated technology, poor patient experience and operational problems at sites cascaded up to the cost and timeline overruns he experienced as an investor. He founded Lindus to fix these problems and provide a more accountable, predictable model for research.
Dr. Beata Godlewska
Principal Investigator
University of Oxford
Panelist
Beata is a Senior Clinical Researcher and Honorary Consultant Psychiatrist at the University of Oxford's Department of Psychiatry, where she has worked since 2007. She received her medical degree and PhD from the University of Gdańsk in Poland before moving to Oxford. Her research focuses on the psychopharmacology of mood disorders, including major depressive disorder and bipolar disorder, with a particular focus on early detection and treatment-resistant forms of these conditions, and on the biological mechanisms of antidepressant drug action. Alongside this, her work has extended into understanding the underlying biology of ME/CFS with a view to future treatment development, which informs her approach as Principal Investigator on ReMEdi. She has maintained clinical practice throughout her academic career, working as an Honorary Consultant Psychiatrist within the Mood Disorders Treatment Clinic since 2010, and brings that combined research and clinical perspective to leading ReMEdi's clinical conduct in a fully remote setting.
Dr. Simon Bock
Clinical and Market Access, Portfolio & Innovation Manager
Tiefenbacher Group
Panelist
Simon is Clinical and Market Access, Portfolio & Innovation Manager at Tiefenbacher Group, where his work spans portfolio planning, study conception, regulatory correspondence, market access, and digital health innovation. His background combines pharmaceutical industry experience with nearly eight years of community pharmacy practice at Priv. Adler Apotheke in Hamburg, an unusual combination that informs how he evaluates whether a development programme will translate into something patients can actually access. At Tiefenbacher, he represents the sponsor on the ReMEdi programme, a fully virtual Phase 2 trial in ME/CFS, and contributes to the broader portfolio strategy for repurposing-led development in neglected and underserved indications, where commercial attractiveness and patient access have to be designed in from the outset rather than bolted on at launch.

Register to attend

This is some text inside of a div block.
This is some text inside of a div block.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.